BAYTRIL MAX 100 MG/ML SOLUTION FOR INJECTION FOR PIGS

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

ENROFLOXACIN

제공처:

Bayer Limited

ATC 코드:

QJ01MA90

INN (International Name):

ENROFLOXACIN

복용량:

100 Mg/Ml

약제 형태:

Solution for Injection

처방전 유형:

POM

치료 그룹:

Porcine

치료 영역:

Enrofloxacin

치료 징후:

Antibacterial

승인 상태:

Authorised

승인 날짜:

2011-09-23

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Baytril Max 100 mg/ml solution for injection for pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
ACTIVE SUBSTANCE:
Enrofloxacin 
100 mg 

EXCIPIENT(S):
n-Butanol
30 mg 
Benzyl alcohol (E 1519) 20 mg 

For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Clear, yellow solution for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pig
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of bacterial bronchopneumonia caused by enrofloxacin-sensitive _Actinobacillus pleuropneumoniae_,
_Pasteurella multocida _and complicated by _Haemophilus parasuis _as secondary pathogen in pigs.
4.3 CONTRAINDICATIONS
Do not use in case of hypersensitivity to the active substance or to any of the excipients. Do not use in case of
resistance against other fluoroquinolone due to the potential for cross-resistance.
Do not use in animals with central nervous system-associated seizure disorders. Do not use in the presence of existing
disorders of cartilage development or musculoskeletal damage around functionally
significant or weight-bearing joints.
Do not use for prophylaxis.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/07/2016_
_CRN 7022663_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Repeated injections should be administered at different sites.
Official, national and regional antimicrobial policies should be taken into account when the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded
poorly, or are expected to respo